12de DUOS Jaarsymposium: prof. Nick James en prof. Alison Birtle spreken

SAVE THE DATE: op de eerste vrijdag in december, dit jaar 2 december,  vindt het DUOS Jaarsymposium weer plaats in Boerderij Mereveld te Utrecht. Internist-oncologen, radiotherapeuten, urologen en andere professionals kunnen onder vermelding van BIG nummer inschrijven via communicatie@stichtingduos.nl.

Het programma verschijnt volgende week op de DUOS site. Als buitenlandse gastsprekers zijn dit jaar uitgenodigd prof. Nick James en prof. Alison Birtle, beiden vooraanstaand specialist uit de UK.

Prof. Nick James  ‘Low volume mCNPC; when to opt for definitive treatment and what is the 2022 approach for delaying mCRPC?

Professor Nick James was also guest speaker on  the DUOS Jaarsymposium 2015 en 2017 (Stampede).

Professor James has degrees in medicine and immunology from the University of London and a PhD from Imperial college in cell cycle biology. He undertook postgraduate training in London, Brussels and Tokyo and is a Fellow of the Royal Colleges of Radiology and Physicians.

His work focuses on evaluating and improving clinical trials to achieve better patient outcomes. He evaluates new treatment approaches to both bladder and prostate cancers via large multi-centre clinical trials and actively collaborates with laboratory groups to explore the underlying mechanisms at play in trials.

‘Clinical trials are the ultimate means of translating scientific advances into real gains in patient survival, or improvements in related outcomes such as prevention of unpleasant complications.They require collaboration of many (often thousands) of participants, both as patients and in the clinical teams recruiting and managing the studies. Good design is thus key for optimising the conduct of trials to maximise return on investment,’ says Nick James.

Prof. Alison Birtle ‘Perioperative management for upper and lower tract UCC’

Dr Alison Birtle is a Consultant Clinical Oncologist based at The Rosemere Cancer Centre, Preston.

Dr Birtle’s specialist interests cover chemotherapy for urological tumours, targeted therapy and radiotherapy developments. She trained in London at Charing Cross and Westminister Medical School and as a specialist registrar in clinical oncology in North Thames. She  completed her MD Thesis at the Institute of Urology, University College London, in PSA negative prostate cancer and finished site specialised training at the  Academic Urology Unit, Royal Marsden Hospital.

In November 2007, Dr Birtle was appointed ‘Honorary Clinical Senior Lecturer’ at The University of Manchester in recognition of her academic and clinical research of cancer.

She was Clinical Lead for Research for Lancs & South Cumbria Cancer Research Network until April 2014 and is a member of the Research and innovation Committee at Lancs Teaching Hospitals NHS Foundation Trust and an active member of the Cancer Research Partnership Group.

Dr Birtle is committee member of the British Uro-Oncology Group and Trustee of the Action on Bladder cancer.

Door de site te blijven gebruiken, ga je akkoord met het gebruik van cookies. meer informatie

Deze site is standaard ingesteld op 'cookies toestaan", om je de beste mogelijke blader ervaring te geven. Als je deze site blijft gebruiken zonder je cookie instellingen te wijzigen, of als je klikt op "Accepteren" hieronder, dan geef je toestemming voor het gebruik van Cookies.